

PATIENT CARD

Important Safety Information for Patients Taking ULTOMIRIS® (ravulizumab)

Ravulizumab can lower the ability of your immune system to fight infections, **especially meningococcal infection, which requires immediate medical attention**. If you experience any of the following symptoms, you should **immediately call your doctor or seek emergency medical care, preferably in a major emergency medical care center**:

- headache with nausea or vomiting
- headache with a stiff neck or stiff back
- fever
- rash
- confusion
- muscle aches with flu-like symptoms
- eyes sensitive to light



Get emergency medical care right away if you have any of these signs or symptoms and show this card.

Keep this card with you at all times during treatment and for 8 months after your last ravulizumab dose. Your risk of meningococcal infection may continue for several months after your last dose of ravulizumab.

PATIENT CARD

Information for the Treating Physician



This patient has been prescribed ravulizumab therapy, which increases the patient's susceptibility to meningococcal infection (*Neisseria meningitidis*) or other general infections.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early
- **Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary**
- Contact prescribing physician (below) as soon as possible

For more information about ravulizumab please refer to local label or contact Biologix on medinfo@biologixpharma.com

To report any side effect(s), please contact:

The National Pharmacovigilance Centre (NPC):

SFDA Call Center: 19999

E-mail: npc.drug@sfd.gov.sa

Website: <https://ade.sfd.gov.sa/>

Or

The local representative of the Marketing Authorisation Holder in KSA:

Biologix, FZ Co,

Hibatullah Al Ghaffari Street-Suliemaniah

Kingdom of Saudi Arabia P.O.Box 991, Riyadh 11421

Biologix Pharmacovigilance Department

Email: pharmacovigilance-ksa@biologixpharma.com

Tel: +966 11 464 6955 Ext: 286

Mobile: +966 55 999 4037

PATIENT CARD

Patients receiving ravulizumab should carry this card at all times.
Show this card to any doctor involved in your health care.

Patient Name _____

Hospital where treated _____

Physician name _____

Tel. number _____



Alexion Pharma Middle East FZ LL
C10th Floor, Office 1007, North Tower
Dubai Science Park HQ Tower
PO box 500594
Dubai - United Arab Emirates



BIOLOGIX FZCo
Hibatullah Al Ghaffari Street-
Sulimaniyah
Kingdom of Saudi Arabia
P.O.Box 991, Riyadh 11421